AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 187.89B +2.1% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 24.06 |
| Forward PE | 15.18 |
| Dividend | 2.39 (1.95%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | n/a |
| Open | 12,200 |
| Previous Close | 12,114 |
| Day's Range | 11,958 - 12,200 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.21 |
| Analysts | Buy |
| Price Target | 15,567.18 (+30.05%) |
| Earnings Date | Oct 30, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 24 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,567p, which is an increase of 30.05% from the latest price.
News
Ionis, AstraZeneca ATTR-CM trial did not meet primary endpoint
The CARDIO-TTRansform trial investigating eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy did not meet its primary efficacy endpoint, according to results presented at the E...
Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data
After Ionis Pharmaceuticals (IONS) and AstraZeneca (AZN) presented full results of the Cardio-TTRansform trial at the ESC Congress 2026 in Munich, Jefferies said the data came in “mostly as expected.”...
Amgen, AstraZeneca announce Crossing trial showed ‘meaningful’ improvements
Positive high-level results from the Phase III CROSSING trial in patients with eosinophilic esophagitis showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant...
AstraZeneca Stock (AZN) Slides Despite New Esophagus Drug Trial Success
Shares in pharmaceuticals giant AstraZeneca ($AZN) and peer Amgen ($AMGN) both dropped in pre-market trading despite hailing successful trial results for a new esophagus drug. AZN said that its asthma...
Amgen, AstraZeneca report CROSSING trial met co-primary and secondary endpoints
Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 CROSSING trial of Tezspire in patients living with eosinophilic esophagitis. Tezspire demonstrated statistically signific...
AstraZeneca's asthma drug Tezspire meets all goals in late-stage esophagitis trial
AstraZeneca said on Thursday its asthma drug, Tezspire, developed with Amgen , met its main and secondary goals in a late-stage trial for treating eosinophilic esophagitis, a chronic infla...
AstraZeneca, Daiichi’s TROPION-Urothelial04 phase 3 trial of Datroway initiated
The first patient has been dosed in the TROPION-Urothelial04 phase 3 trial evaluating Datroway plus rilvegostomig or Datroway monotherapy versus current standard of care as an adjuvant treatment in pa...
AstraZeneca initiated with an Outperform at CICC
CICC analyst Yuan Guo initiated coverage of AstraZeneca (AZN) with an Outperform rating and $198 price target The firm views the company’s pipeline as “excellent,” with potential catalysts including a...
AstraZeneca initiated with an Outperform at CICC
CICC initiated coverage of AstraZeneca (AZN) with an Outperform rating and 14,514 GBp price target
Is It Too Late to Buy AstraZeneca PLC (AZN) After 3.0% Rally? GF Value Says Undervalued
Is It Too Late to Buy AstraZeneca PLC (AZN) After 3.0% Rally? GF Value Says Undervalued
The Key to Pharma M&A: Never Shopping Hungry
Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.
PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend
Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says Get our breaking news email , free app or daily news podcast The fede...
Information Services Group, Inc.: ISG Event to Spotlight Strategies for the AI-Driven Autonomous Enterprise
Leaders from Lloyds Banking Group, NatWest, Ogilvy, AstraZeneca, Diageo, Reckitt, Carlsberg, Shell and more to join ISG AI Impact Summit London Information Services Group (ISG) (Nasdaq: III), a gl...
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch
AstraZeneca Halts Key Lung-Cancer Trial--But Shares Barely Flinch
AZN Looks 12.9% Undervalued on GF Value⢠Amid Dividend Sustainability
AZN Looks 12.9% Undervalued on GF Value⢠Amid Dividend Sustainability
AstraZeneca to discontinue eVOLVE-Lung02 Phase III trial
AstraZeneca (AZN) announced that it is discontinuing the eVOLVE-Lung02 Phase III trial evaluating volrustomig in combination with chemotherapy as a 1st-line therapy compared to pembrolizumab and chemo...
AZN Looks 12.9% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 12.9% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 12.9% Undervalued on GF Value⢠with Solid Dividend Fundamentals
AZN Looks 12.9% Undervalued on GF Value⢠with Solid Dividend Fundamentals
AstraZeneca announces results from DESTINY-Lung04 trial of Enhertu
Results from the DESTINY-Lung04 Phase III trial showed Enhertu demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus global standard of car...
AstraZeneca announces results from Phase III trial of Tagrisso, savolitinib
Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free su...
AstraZeneca announces results from Phase III trial of Tagrisso, savolitinib
Positive high-level results from the Saffron Phase III trial showed Tagrisso plus savolitinib demonstrated a statistically significant and clinically meaningful improvement in both progression-free su...
TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the SAFFRON Phase III trial showed TAGRISSO® (osimertinib) plus savolitinib demonstrated a statistically significant and clinically ...
FTSE 100 set to snap six-day losing streak as miners gain
Britain's FTSE 100 edged higher on Monday, on track to end six straight days of losses, as strength in mining stocks, AstraZeneca and Rolls-Royce offset broader caution ahead of this week's UK inflati...
AstraZeneca Discontinues Phase 3 EVOLVE-Lung02 Trial Of Volrustomig In Non-small Cell Lung Cancer
(RTTNews) - AstraZeneca PLC (AZN), on Monday said it is discontinuing the Phase 3 eVOLVE-Lung02 trial evaluating Volrustomig plus chemotherapy as a first-line treatment for patients with metastatic no...
AZN Looks 12.9% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals
AZN Looks 12.9% Undervalued on GF Value⢠Amid Solid Dividend Fundamentals